China biotech 3SBio said it has signed an exclusive licensing deal with South Korea's Alteogen for the development, manufacturing and marketing of ALT-P7, an antibody-drug conjugate used in cancer treatments, keeping it on a steady deal streak since a public relisting this summer.
South Korea's SK Chemicals said domestic sales of the country's first cell-culture flu vaccine, SKYCellflu, passed 1 million doses within two weeks of launch. Plans for sales abroad are also in the cards.
A thwarted challenge from an activist investor to block the $8 billion merger of Samsung C&T and Cheil Industries last week has set the stage for family-controlled Samsung Electronics and related units to focus on boosting already rapid growth at Samsung BioLogics and Samsung Bioepis, the Korea Herald reports.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
South Korea has set out plans to spend an additional KRW10 trillion ($9 billion) to manage the outbreak of Middle East respiratory syndrome that has afflicted 179 and caused 27 deaths since May, news reports said.
Two South Korean firms, Corestem and Kyongbo Pharmaceutical, this week showed solid investor demand for biopharma stocks in the country.
Clinical studies of an experimental plasma therapy to treat Middle East respiratory syndrome (MERS) are underway in two South Korea hospitals, according to news agency reports, citing the country's health ministry.
On Monday, South Korea moved to reopen schools shut last week on concerns of a wider spread of Middle East respiratory syndrome (MERS) even as the health ministry reported 5 new cases and regional governments kept up precautions, according to Today newspaper.
South Korea's Celltrion and Samsung Bioepis are poised to gain new or expanded approval for biosimilars of some of the world's best-selling biological drugs, setting up a regulatory knowledge base on approvals and bringing commercial competition to major drugmakers not unlike that seen by small-molecule generics from India decades ago.
Governments in Asia are acutely sensitive about the possible wider spread of Middle East respiratory syndrome (MERS) for good reason--many of them learned the lesson of not acting quickly in 2002 and 2003 when severe acute respiratory syndrome (SARS) hit economies from Hong Kong to Singapore as China originally underplayed the initial cases.